Am J Obstet Gynecol:17α-己酸羟孕酮对预防复发性早产到底有没有用?

2017-06-30 Emma MedSci原创

在美国,17α-己酸羟孕酮被推荐使用来预防复发性早产。发表于Am J Obstet Gynecol的一篇文章中,研究人员通过与17α-己酸羟孕酮使用之前的数据相比较,来评估17α-己酸羟孕酮对于预防不超过35周复发性早产的临床疗效。

很多研究报道,17α-己酸羟孕酮能够预防复发性早产。发表于Am J Obstet Gynecol的一篇文章中,研究人员通过与17α-己酸羟孕酮使用之前的数据相比较,来评估17α-己酸羟孕酮对于预防≤35周复发性早产的临床疗效。研究主要指标是与16.8%复发性早产的历史数据相比,≤35周早产的复发率。三个次级指标,第一,根据研究对象早产和足月分娩的数量和先后顺序,17α-己酸羟孕酮有没有使其状况改善?第二,早产的复发与17α-己酸羟孕酮血浆浓度是否相关?第三,与先前早产的妊娠持续时间相比,17α-己酸羟孕酮的治疗是否改变了妊娠持续时间?

430名有≤35周早产病史的女性从2012年1月至2016年3月接受连续的17α-己酸羟孕酮治疗。其中近三分之二的女性(N = 267)在妊娠18周前开始接受注射,394名(92%)女性接受每周定期注射直到分娩或者妊娠35周前10天。

结果显示,整个研究群体的复发性早产率是25% (N = 106),与历史数据16.8%相比差异不显著(P = 1.0),三个次级指标结果也为阴性。不管研究对象早产和足月分娩的数量和先后顺序如何,17α-己酸羟孕酮没有显著降低早产复发率;≤35周分娩的女性和35周后分娩的女性17α-己酸羟孕酮血浆浓度差异不显著;在使用17α-己酸羟孕酮前,复发性早产的周数平均是0.4±5.3周,而使用17α-己酸羟孕酮后,这一数据是0.1±4.7周,差异不显著(P = 0.63)。除此之外,每周定期注射17α-己酸羟孕酮还表现出副作用,即妊娠糖尿病的增加,经17α-己酸羟孕酮治疗的女性妊娠糖尿病率为13.4%,而对照组仅为8%(P = 0.001)。

该研究结果说明,17α-己酸羟孕酮对预防复发性早产无效,甚至与妊娠糖尿病发病率有关,或许应该停止其在预防复发性早产中的使用。

原始出处:
Nelson, D. B., et al. 17-alpha Hydroxyprogesterone Caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study. Am J Obstet Gynecol. 2017 Jun;216(6):600.e1-600.e9. doi: 10.1016/j.ajog.2017.02.025.

本文系梅斯医学(MedSci)原创翻译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2011323, encodeId=081f201132334, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Jul 20 01:29:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909644, encodeId=0bd81909644cf, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Feb 18 16:29:00 CST 2018, time=2018-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043987, encodeId=0c0f204398e71, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Jan 07 18:29:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471036, encodeId=394614e10362c, content=<a href='/topic/show?id=0b1445323b0' target=_blank style='color:#2F92EE;'>#孕酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45323, encryptionId=0b1445323b0, topicName=孕酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fea57099634, createdName=周虎, createdTime=Sat Jul 01 17:29:00 CST 2017, time=2017-07-01, status=1, ipAttribution=)]
    2017-07-20 yhy100200
  2. [GetPortalCommentsPageByObjectIdResponse(id=2011323, encodeId=081f201132334, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Jul 20 01:29:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909644, encodeId=0bd81909644cf, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Feb 18 16:29:00 CST 2018, time=2018-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043987, encodeId=0c0f204398e71, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Jan 07 18:29:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471036, encodeId=394614e10362c, content=<a href='/topic/show?id=0b1445323b0' target=_blank style='color:#2F92EE;'>#孕酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45323, encryptionId=0b1445323b0, topicName=孕酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fea57099634, createdName=周虎, createdTime=Sat Jul 01 17:29:00 CST 2017, time=2017-07-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2011323, encodeId=081f201132334, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Jul 20 01:29:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909644, encodeId=0bd81909644cf, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Feb 18 16:29:00 CST 2018, time=2018-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043987, encodeId=0c0f204398e71, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Jan 07 18:29:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471036, encodeId=394614e10362c, content=<a href='/topic/show?id=0b1445323b0' target=_blank style='color:#2F92EE;'>#孕酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45323, encryptionId=0b1445323b0, topicName=孕酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fea57099634, createdName=周虎, createdTime=Sat Jul 01 17:29:00 CST 2017, time=2017-07-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2011323, encodeId=081f201132334, content=<a href='/topic/show?id=840d1e300e5' target=_blank style='color:#2F92EE;'>#TET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17300, encryptionId=840d1e300e5, topicName=TET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cc52251, createdName=yhy100200, createdTime=Thu Jul 20 01:29:00 CST 2017, time=2017-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909644, encodeId=0bd81909644cf, content=<a href='/topic/show?id=8f1f42518d8' target=_blank style='color:#2F92EE;'>#复发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42518, encryptionId=8f1f42518d8, topicName=复发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Sun Feb 18 16:29:00 CST 2018, time=2018-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043987, encodeId=0c0f204398e71, content=<a href='/topic/show?id=8513126129d' target=_blank style='color:#2F92EE;'>#NEC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12612, encryptionId=8513126129d, topicName=NEC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Jan 07 18:29:00 CST 2018, time=2018-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1471036, encodeId=394614e10362c, content=<a href='/topic/show?id=0b1445323b0' target=_blank style='color:#2F92EE;'>#孕酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45323, encryptionId=0b1445323b0, topicName=孕酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fea57099634, createdName=周虎, createdTime=Sat Jul 01 17:29:00 CST 2017, time=2017-07-01, status=1, ipAttribution=)]
    2017-07-01 周虎

相关资讯

AJOG:BMI对孕激素类药物预防早产疗效的影响

早产是导致新生儿死亡及短期或长期致残的主要原因,其中40%的早产发生在妊娠34周前,20%发生在32周前。妊娠34周前的早产占围产儿死亡及病率的50%。如何延长孕周以降低围产儿死亡率及病率是早产防治的关键。2003年《新英格兰医学杂志》刊登的一篇随机对照临床试验结果表明,每周注射17α-己酸羟孕酮可减少既往有早产史的单胎孕妇复发性早产的发生,降低婴儿严重并发症的发生风险。随后陆续有相关研究报道证实